Correction of high myopic astigmatism

Article

Results of surgical iLASIK procedure indicate better predictability

Wavefront guided ablations with Advanced CustomVue (Abbott Medical Optics, Santa Ana, California, USA) have been proven to be a very effective and safe way to correct myopia and myopic astigmatism.3 Among other technological features, the aforementioned procedure incorporates Iris Registration (IR), which is responsible for compensating any degree of ciclotorsion and pupil centroid shift that happens when the patient lies down under the laser and pupil changes size respectively. No study has been published yet addressing the outcome of this technology in patients with a high degree of astigmatism undergoing femtoLASIK surgery.

We designed a prospective open label comparative study with the objective of evaluating the efficacy, safety and predictability of the iLASIK procedure that combines the Advanced CustomVue procedure and Intralase FS60 (Abbott Medical Optics), in high myopic astigmatism and compare it with the standard femtoLASIK with the VISX S4 (Abbott Medical Optics). The main inclusion criteria was to have a compound myopic astigmatism with a cylinder ranging from 2 up to 5 D and sphere up to –6 D.4

Patients were followed up for a period of 3 months after surgery, including the following measurements uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), predictability, efficacy and safety. Refractive error and visual acuity were treated as continuous variables and analysed for significance by independent t test.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.